CVSA stock forecast, quote, news & analysis

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 67 cases where CVSA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 64%.

The Moving Average Convergence Divergence Histogram (MACD) for CVSA turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 29 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.

CVSA moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVSA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.

Bullish Trend Analysis

The 10-day moving average for CVSA crossed bullishly above the 50-day moving average on October 19, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 76%.

Following a +3.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where CVSA advanced for three days, in 290 of 389 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.

CVSA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 178 of 269 cases where CVSA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 66%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 34 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. CVSA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 51 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.923) is normal, around the industry mean (1.252). P/E Ratio (17.297) is within average values for comparable stocks, (9.236). Projected Growth (PEG Ratio) (0.866) is also within normal values, averaging (1.327). Dividend Yield (0.000) settles around the average of (3.575) among similar stocks. P/S Ratio (2.325) is also within normal values, averaging (27.566).